Impact of Photobiomodulation (PBM) on Biomarkers of Radiation Lymphedema and Fibrosis in Head and Neck Cancer Patients

Inclusion Criteria: * Patients treated with radiation for head and neck cancer who are ≥ 3 months \< 36 months post-RT (last RT). * Patients who received at least 50Gy of bilateral neck RT. Subjects who received RT or concurrent chemoradiation (chemoRT) therapy for HNC are eligible. * No evidence of disease as documented by imaging 3 months after completion of RT. * Common Terminology Criteria for Adverse Events (CTCAE) fibrosis score ≥ 2 at enrollment. * Patient who has body mass index (BMI) \>30 at the time of enrollment may be excluded at a discretion of the principal investigator if fibrotic areas cannot be identified by clinical objective assessment of fibrosis. * Willing to comply with all study procedures and be available for the duration of the study. Exclusion Criteria: * Woman who are pregnant or planning to become pregnant or breast-feeding. * Patients enrolled on another drug or device investigational trial for prevention or treatment of LEF. * Patients deprived of freedom, under supervision or guardianship. * Patients unable to attend to scheduled visits due to geographical, social or mental reasons. * Patients who received prior PBM therapy for RT toxicities in the last year; * Patients who report being photosensitive. * Patients who have chronic immunosuppression or are on current immunosuppressive therapies. * Any patient who, in the opinion of the investigator, is unable or unlikely to comply fully with the study requirements or procedures for any reason.